Project Grant R01CA316351
- Federal Grant Award Summary Cold Spring Harbor Laboratory received a $704,182 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 16, 2026, with an ultimate completion date of May 31, 2031. The award funds fundamental research aimed at elucidating the non-mutational mechanisms underlying the benign-to-malignant transition in colorectal cancer (CRC). The research deliverables include the development and utilization...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $182,755.00 to Cold Spring Harbor Laboratory through the Cancer Biology Research program (CFDA 93.396) to support research on genetic technology development for elucidating lineage plasticity mechanisms in cancer. The project, which commenced on August 21, 2025, and is scheduled for completion on July 31, 2030, will deliver advanced genetic screening technologies and methodologies designed to probe lineage identity...
- Federal Grant Award Summary The National Cancer Institute awarded a $2.49M Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research, effective August 1, 2025, through July 31, 2030. This research initiative comprises three integrated projects investigating lipid metabolism as a determinant of ferroptosis sensitivity in cancer cells. Project 1, led by Dr. Xuejun Jiang at Memorial Sloan Kettering Cancer Institute, examines how...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Project Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $452,540 under the Cancer Biology Research program (CFDA 93.396) to conduct a two-year research project from May 1, 2026 through April 30, 2028. The project, titled "Innate & Adaptive Determinants of Post-CAR Cytokine Release Syndrome," investigates the mechanisms underlying cytokine release syndrome (CRS)—a severe inflammatory response occurring in 93% of...
- Federal Project Grant Award Summary The Sloan-Kettering Institute for Cancer Research received an $880,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective August 1, 2025, through May 31, 2030. The research project investigates the mechanisms of lipid droplet (LD) protein targeting in human cells, addressing fundamental gaps in cell biology understanding. The project will...
- Federal Project Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $609,493 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded June 1, 2025, with a completion date of May 31, 2030. This five-year research initiative will generate fundamental scientific knowledge regarding the protein machinery and molecular mechanisms underlying lipid droplet (LD)...
- Grant Award Summary The National Cancer Institute (NCI) awarded a $450,904 Project Grant to the Pacific Northwest National Laboratory (PNNL), a division of Battelle Memorial Institute, under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. The funded project will develop a novel single-cell (phospho-)proteomics platform designed to characterize tumor microenvironment (TME) components—including cancer cells, immune cells, and stromal...
- Federal Grant Award Summary Cold Spring Harbor Laboratory (CSHL) received a $518,342 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period July 1, 2025 through June 30, 2028. The award supports basic biomedical research investigating communication mechanisms between cancer-associated fibroblasts and neurons in pancreatic cancer progression. This three-year research initiative aligns with the DHA's mission...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Health Sciences Division a $501,422 Project Grant under the Cancer Biology Research program (CFDA 93.396) commencing May 1, 2026, with completion targeted for April 30, 2031. This award supports fundamental research to advance understanding of synthetic lethal (SL) vulnerabilities in specific cancer subtypes, with the ultimate objective of developing novel precision oncology therapeutics. The research...
Cold Spring Harbor Laboratory (CSHL) received a $770,911 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026 through June 30, 2031. The research focuses on defining the role of sphingolipid synthesis in anti-tumor immunity, with the objective of identifying molecular pathways that link tumor lipid metabolism to immune evasion. The project builds on preliminary in vivo genetic screening findings in KRAS-mutant mouse models of pancreatic and colorectal cancers, which identified serine palmitoyl transferase (SPT)-catalyzed sphingolipid synthesis as a critical metabolic requirement for tumor growth that is dependent on an intact immune system. Loss of sphingolipid synthesis sensitizes cancer cells to natural killer (NK) cell and T cell-mediated killing. The research deliverables will include detailed mechanistic studies testing the hypothesis that sphingolipid availability in tumors mediates immune evasion, as well as assessments of how dietary fats impact tumor growth and anti-tumor immunity. These investigations will evaluate the therapeutic potential of sphingolipid synthesis inhibition through both genetic and pharmacologic approaches, with the ultimate goal of identifying dietary and pharmacological interventions that leverage lipid metabolism to enhance immune-mediated tumor suppression across diverse cancer types.Federal Project Grant Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $770.9k | 6/16/26 |